

## An Enantiospecific Synthesis of Solenopsin A

Charles W. Jefford\* and Jian Bo Wang

Department of Organic Chemistry, University of Geneva 1211 Geneva 4, Switzerland

Key words: 2,6-Dialkylpiperidine, innate chirality, hydride reduction, iminium cation


**Abstract:** Enantiomerically pure solenopsin A (**1**) was prepared in 11 steps from L-aspartic acid (**3**) in an overall yield of 17%. 6*R*-(*N*-tosylamino)heptadecan-2-one (**8**), prepared from **3**, underwent cyclization on acid catalysis to *N*-tosylamino-2,3-dehydro-2-methyl-6*R*-undecylpiperidine (**9**), which on reduction and deprotection gave **1**.

The solenopsins A and B (**1** and **2**) are constituents of the venom of the fire ant, *Solenopsis invicta* (= *S. saevissima*), the habitat of which is the south-east part of the United States of America (Scheme 1).<sup>1</sup> Both molecules are biologically active in having hemolytic, insecticidal and antibiotic properties.<sup>2</sup> Despite the apparent simplicity of their structures, the synthesis of the enantiomerically pure isomers is not trivial.<sup>3,4</sup> The essential problem lies in the creation of the *trans* configuration for the 2,6-dialkyl substituents. So far four solutions have been reported. The first entails the transfer of chirality on successive alkylations of 2-cyano-6-oxazolopiperidine.<sup>5</sup> The second involves the diastereoselective reduction of a bornyl  $\beta$ -keto ester to a chiral secondary alcohol which by conversion to its azide and subsequent internal dipolar addition controls the construction of the 2-methylpiperidine ring.<sup>6</sup> The third depends essentially on the cyclization of 6*R*-aminoheptadecan-2-one to the related 1,2-dehydropiperidine which is then selectively reduced.<sup>7</sup> The fourth solution exploits the innate chirality of 5-methyl L-glutamate which on elaboration provides an analogous amino-ketone which undergoes stereocontrolled cyclization.<sup>8,9</sup> We now describe a practical enantiospecific synthesis of **1** that embodies the chief features of the last two approaches, but which takes advantage of our procedure for preparing enantiomerically pure  $\beta$ -amino acids from aspartic acid.<sup>10</sup>


Scheme 1




L-Aspartic acid (**3**) was first transformed in 4 steps into the key intermediate,<sup>10</sup> the *N*-protected iodohomoserine ester **4** (Scheme 2). Next, treatment of **4** with lithium didecylcuprate in THF gave the undecyl- $\beta$ -amino ester **5** in 86% yield. Reduction of the ester group with diisobutylaluminum hydride (DIBAH) furnished the corresponding aldehyde **6** in similar yield. Wittig reaction with acetylmethylidetriphenylphosphorane gave exclusively the  $\alpha,\beta$ -unsaturated ketone **7**, which was hydrogenated over Adams catalyst to the methyl ketone **8**. Both **7** and **8** were formed in essentially quantitative yield.<sup>11</sup> Cyclization was achieved by catalysis with *p*-toluenesulfonic acid. The resulting dehydropiperidine **9**, obtained in 73% yield,<sup>11</sup> was then submitted to sodium cyanoborohydride in the presence of trifluoroacetic acid (TFA) in CH<sub>2</sub>Cl<sub>2</sub>. Reduction afforded the *trans* and *cis* piperidines **10** and **11** as an inseparable mixture in a ratio of 7:2 in 98% yield.<sup>12</sup> The identity of each isomer was confirmed by the independent preparation of the *cis* isomer **11** by the catalytic hydrogenation of **9**.<sup>13</sup>



Finally, deprotection of the isomers was effected with sodium naphthalide in dimethoxyethane (DME) (Scheme 3). Purification of the resulting oil by column chromatography over alkaline  $\text{Al}_2\text{O}_3$  delivered pure solenopsin A (**1**) of the 2R,6R configuration in 72% yield.<sup>14</sup> The synthetic solenopsin A possesses spectral data identical to those of the natural material and displays commensurate optical activity.<sup>15</sup>



The reduction of **9** proceeded with significant stereocontrol (*trans*:*cis* ratio = 7:2). Nevertheless, comparison with similar reductions of the *N*-*t*-butoxycarbonyl,<sup>4k</sup> and *N*-benzyl<sup>4i</sup> analogues of **9** (*trans*:*cis* ratio = 9:1) suggests that the *N*-tosyl group in the iminium cation **13** derived from **9** is not so susceptible to  $\text{A}^{1,2}$  strain.<sup>16</sup> In other words, the preference for the axial half-chair conformation and its attack by hydride (**13a**  $\rightarrow$  **10**) over its equatorial counterpart (**13e**  $\rightarrow$  **11**) is less marked (Scheme 4).



The advantages of the present synthesis are its operational simplicity and conciseness. The same procedure should also be applicable for preparing 2,5-dialkylpyrrolidines of natural occurrence. Such studies are under way and the results will be reported in due course.

*Acknowledgment.* We thank the National Science Foundation (grant No 20-32'166.91) for support of this work.

#### REFERENCES AND NOTES

1. J.G. MacConnell, M.S. Blum, H.M. Fales, *Tetrahedron* **1971**, *27*, 1129.
2. G.A. Androuny, V.J. Derbes, R.C. Jung, *Science* **1959**, *130*, 449.
3. For reviews on the synthesis of piperidines see: C.J. Wang, M.A. Wuonola, *Org. Prepn. Procedures Int.* **1992**, *24*, 583; M. Rubiralta, E. Giralt, A. Diez "Piperidine: Structure, Preparation, Reactivity and Synthetic Applications of Piperidine and its Derivatives", Elsevier, New York, N.Y. **1991**.
4. Many syntheses of racemic solenopsins (A and B) have been reported: a) K. Fuji, K. Ichikawa, E. Fujita, *Chem. Pharm. Bull.* **1979**, *27*, 3183; b) Y. Matsumura, K. Maruoka, H. Yamamoto, *Tetrahedron Lett.* **1982**, *23*, 1929; c) S. Sakane, Y. Matsumura, Y. Yamamura, Y. Ishida, K. Maruoka, H. Yamamoto, *J. Am. Chem. Soc.* **1983**, *105*, 672; d) W. Carruthers, M.J. Williams, M.T. Cox, *J. Chem. Soc., Chem. Commun.* **1984**, 1235; e) Y. Nakazono, R. Yamaguchi, M. Kawanishi, *Chem. Lett.* **1984**, 1129; f) B.P. Mundy, M. Bjorklund, *Tetrahedron Lett.* **1985**, *26*, 3899; g) K.K. Takahashi, H. Kurita, K. Ogura, H. Iida, *J. Org. Chem.* **1985**, *50*, 4368; h) R. Yamaguchi, Y. Nakazono, T. Matsuki, E. Hata, M. Kawanishi, *Bull. Chem. Soc. Jpn.* **1987**, *60*, 215; i) H.H. Wasserman, V. Rusiecki, *Tetrahedron Lett.* **1988**, *29*, 4977; j) T. Nagasaka, H. Hayashi, M. Kumakawa, M. Sakamoto, *Heterocycles* **1989**, *29*, 2157; k) D.L. Comins, M.A. Weglarz, *J. Org. Chem.* **1991**, *56*, 2506.
5. D.S. Grierson, J. Royer, L. Guerrier, H.-P. Husson, *J. Org. Chem.* **1986**, *51*, 4475.
6. D.F. Taber, P.B. Decker, H.M. Fales, T.H. Jones, H.A. Lloyd, *J. Org. Chem.* **1988**, *53*, 2968.
7. Y. Ukaji, T. Watai, T. Sumi, T. Fujisawa, *Chem. Lett.* **1991**, 1555.
8. H. Kotsuki, T. Kusumi, M. Inoue, Y. Ushio, M. Ochi, *Tetrahedron Lett.* **1991**, *32*, 4159.
9. Yet another approach started from optically active 6-methyl-2-piperidone. Unfortunately, conversion to solenopsin A by means of the N-acyllactam rearrangement was not really successful as the yield was so poor: R.K. Hill, T. Yuri, *Tetrahedron* **1977**, *33*, 1569.
10. C.W. Jefford, J.B. Wang, *Tetrahedron Lett.* **1993**, in press.
11. Compounds 5-9 were obtained in a pure state by column chromatography over silica gel (eluent: hexane: EtOAc). All are oils, except 8 which is crystalline (m.p. 65-66°C, from hexane). Optical rotations ( $[\alpha]_D^{20}$ ) were determined in  $\text{CHCl}_3$  and had the following values: 5, +14.2° (c 1.4); 6, +13.1° (c 1.3); 7, +36.1° (c 1.1); 8, +9.2° (c 1.1); 9, -178.4° (c 1.5).  $^1\text{H-NMR}$  (200 MHz,  $\text{CDCl}_3$ ): 5, 0.86 (t,  $J = 6.7$  Hz, 3H), 1.20 (t,  $J = 7.1$  Hz, 3H), 1.10-1.60 (m, 20H), 2.37 (dd,  $J = 2.0, 5.2$  Hz, 2H), 2.40 (s, 3H), 3.40 (m, 1H), 4.05 (qd,  $J = 7.1, 1.2$  Hz, 2H), 5.26 (d,  $J = 9.0$  Hz, 1H), 7.26 (d,  $J = 8.4$  Hz, 2H), 7.73 (d,  $J = 8.5$  Hz, 2H); 6, 0.87 (t,  $J = 6.8$  Hz, 3H), 1.05-1.51 (m, 20H), 2.41 (s, 3H), 2.59 (t,  $J = 1.2$  Hz, 1H), 2.62 (t,  $J = 0.4$  Hz, 1H), 3.49-3.61 (m, 1H), 4.86-4.93 (t, br, 1H), 7.29 (d,  $J = 8.5$  Hz, 2H), 7.73 (d,  $J =$

- 8.2 Hz, 2H), 9.62 (t,  $J = 1.2$  Hz, 1H); 7, 0.86 (t,  $J = 6.8$  Hz, 3H), 1.07-1.50 (m, 20H), 2.16 (s, 3H), 2.33 (dd,  $J = 7.3, 13.0$  Hz, 2H), 2.40 (s, 3H), 3.23-3.38 (m, 1H), 4.58 (d,  $J = 8.2$  Hz, 1H), 5.96 (d,  $J = 15.8$  Hz, 1H), 6.60 (dt,  $J = 15.8, 7.3$  Hz, 1H), 7.27 (d,  $J = 8.1$  Hz, 2H), 7.73 (d,  $J = 8.1$  Hz, 2H); 8, 0.88 (t,  $J = 6.7$  Hz, 3H), 1.05-1.41 (m, 24H), 2.09 (s, 3H), 2.33 (t,  $J = 6.9$  Hz, 2H), 2.42 (s, 3H), 3.15-3.22 (m, 1H), 4.40 (d,  $J = 8.1$  Hz, 1H), 7.29 (d,  $J = 8.1$  Hz, 2H), 7.75 (d,  $J = 8.4$  Hz, 2H); 9, 0.88 (t,  $J = 6.7$  Hz, 3H), 1.26 (s, br, 20H), 1.05-1.90 (m, 4H), 2.12 (s, br, 3H), 2.40 (s, 3H), 4.04-4.18 (m, 1H), 4.99-5.06 (m, 1H), 7.27 (d,  $J = 8.1$  Hz, 2H), 7.66 (d,  $J = 8.1$  Hz, 2H).
12. Reduction of 9 with NaCNBH<sub>3</sub>/TFA at -45°C gave the *trans* and *cis* N-tosyl piperidines 10 and 11. The crude oil was purified over silica gel (eluent, hexane: EtOAc 4:1). The isomer ratio was estimated from the intensity of the C2-H and Me signals. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) 0.88 (t,  $J = 6.8$  Hz, 3H), 1.23 (d,  $J = 6.9$  Hz, 0.78 x 3H, *trans* isomer), 1.25 (m, br, 18H), 1.30 (d,  $J = 6.9$  Hz, 0.22 x 3H, *cis* isomer), 1.35-1.82 (m, 8H), 2.40 (s, 3H), 3.56-3.67 (m, 0.78H, *trans* isomer), 3.93-4.01 (m, 0.22H, *cis* isomer), 4.10-4.20 (m, 1H), 7.25 (d,  $J = 8.4$  Hz, 2H), 7.71 (d,  $J = 8.4$  Hz, 2H).
13. A pure sample of the *cis* isomer (11) was obtained by hydrogenation of 9 over 10% Pd/C in MeOH. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 0.89 (t,  $J = 6.8$  Hz, 3H), 1.20-1.41 (m, 20H), 1.30 (d,  $J = 6.9$  Hz, 3H), 1.46-1.80 (m, 6H), 2.41 (s, 3H), 3.92-3.99 (m, 1H), 4.10-4.18 (m, 1H), 7.26 (d,  $J = 8.4$  Hz, 2H), 7.71 (d,  $J = 8.4$  Hz, 2H).
14. Good separation was obtained by using basic aluminum oxide, Fluka, type 5016, and eluting with Et<sub>2</sub>O and then Et<sub>2</sub>O containing 1% *i*-PrNH<sub>2</sub>. The *cis* isomer (12), isosolenopsin A, was also obtained as an oil (17% yield): HCl salt [ $\alpha$ ]<sub>D</sub><sup>22</sup> = -10.6° (c = 0.33, CHCl<sub>3</sub>); IR 2927, 2854, 1602, 1461, 1377, 1261, 1097, 1016, 937, 875, 804; <sup>1</sup>H-NMR (200 MHz, CDCl<sub>3</sub>): 0.86 (t,  $J = 6.8$  Hz, 3H), 1.06 (d,  $J = 6.2$  Hz, 3H), 1.24 (s, br, 18H), 1.30-1.98 (m, 9H), 2.41-2.52 (m, 1H), 2.53-2.70 (m, 1H); <sup>13</sup>C-NMR (50 MHz, CDCl<sub>3</sub>): 14.06, 22.63, 22.90, 24.76, 25.93, 29.29, 29.55, 29.58, 29.61, 29.77, 31.86, 32.02, 34.22, 37.24, 52.47, 57.11.
15. Pure solenopsin A (1) was isolated as an oil in 72% yield: [ $\alpha$ ]<sub>D</sub><sup>20</sup> = -1.30° (c = 1.3, MeOH), lit.<sup>7</sup> [ $\alpha$ ]<sub>D</sub><sup>23</sup> = -2.2° (c = 0.8, MeOH); HCl salt m.p. 147-150°C, lit.<sup>5</sup> 146°C; HCl salt [ $\alpha$ ]<sub>D</sub><sup>20</sup> = -7.7° (c = 0.51, CHCl<sub>3</sub>), lit.<sup>7</sup> [ $\alpha$ ]<sub>D</sub><sup>23</sup> = -7.6° (c = 0.7, CHCl<sub>3</sub>); free base, <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 0.88 (t,  $J = 6.8$  Hz, 3H), 1.07 (d,  $J = 6.6$  Hz, 3H), 1.26 (s, br, 18H), 1.38-1.70 (m, 9H), 2.83-2.90 (m, 1H), 3.12-3.20 (m, 1H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>): 14.08, 19.58, 21.24, 22.66, 26.46, 29.33, 29.62, 29.64, 29.78, 30.82, 31.90, 33.01, 34.10, 45.82, 50.82; MS 252 (42), 238 (100), 224 (11), 210 (22), 184 (38), 98 (99); Anal. calcd for HCl salt, C<sub>17</sub>H<sub>36</sub>ClN: C, 70.43; H, 12.52; N, 4.83; found C, 70.24; H, 12.40; N, 4.72;
16. F. Johnson, *Chem. Rev.* **1968**, *68*, 375.

(Received in Germany 8 February 1993)